Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mathieu Roumiguié is active.

Publication


Featured researches published by Mathieu Roumiguié.


European Urology | 2011

Ureteral and Multifocal Tumours Have Worse Prognosis than Renal Pelvic Tumours in Urothelial Carcinoma of the Upper Urinary Tract Treated by Nephroureterectomy

Adil Ouzzane; Pierre Colin; Evanguelos Xylinas; Géraldine Pignot; Mehdi Mokhtar Ariane; Fabien Saint; Nicolas Hoarau; Emilie Adam; Marie Dominique Azemar; H. Bensadoun; Luc Cormier; Olivier Cussenot; Alain Houlgatte; G. Karsenty; Franck Bruyère; Charlotte Maurin; François Xavier Nouhaud; Véronique Phé; Thomas Polguer; Mathieu Roumiguié; Alain Ruffion; Morgan Rouprêt

BACKGROUND It is not known whether the primary tumour location of upper urinary tract urothelial carcinoma (UUT-UC) is associated with prognosis. OBJECTIVE To evaluate the impact of initial primary tumour location on survival in patients who had undergone radical nephroureterectomy (RNU). DESIGN, SETTING, AND PARTICIPANTS Using a multi-institutional, retrospective database, we identified 609 patients with UUT-UC who had undergone RNU between 1995 and 2010. Tumour location was categorised as renal pelvis, ureter, or multifocal. INTERVENTION All patients had undergone RNU. MEASUREMENTS Tumour location was tested as a prognostic factor for survival through univariate and multivariable Cox regression analysis. RESULTS AND LIMITATIONS Tumour location was renal pelvis in 317 cases (52%), ureter in 185 cases (30%), and multifocal in 107 cases (18%). Compared to renal pelvic and ureteral tumours, multifocal tumours were more likely to be associated with advanced stages (pT3/pT4; 39%, 30%, and 54%, respectively; p<0.001) and high-grade disease (53%, 56%, and 76%, respectively; p<0.001). On multivariable analysis, tumour location was an independent prognostic factor for cancer-specific death, disease recurrence, and metastasis (p<0.05). The 5-yr cancer-specific death-free survival probability was 86.8% for renal pelvic tumours, 68.9% for ureteral tumours, and 56.8% for multifocal tumours (p<0.001). The retrospective design of this study was its main limitation. CONCLUSIONS Ureteral and multifocal tumours had a worse prognosis than renal pelvic tumours. These findings are not in line with recently published data and should be investigated in a prospective assessment to obtain a definitive statement regarding this matter.


Cancer | 2011

Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.

Maria Vassilakopoulou; Thibault de la Motte Rouge; Pierre Colin; Adil Ouzzane; David Khayat; Meletios‐Athanasios Dimopoulos; Christos A. Papadimitriou; Aristotle Bamias; Géraldine Pignot; François Xavier Nouhaud; Sophie Hurel; Laurent Guy; Pierre Bigot; Mathieu Roumiguié; Morgan Rouprêt

Urothelial carcinoma of the upper urinary tract (UUT‐UC) was a rare, aggressive urologic cancer with a propensity for multifocality, local recurrence, and metastasis. High‐risk patients had poor outcomes. Because of the rarity of these tumors, randomized clinical trials and data regarding adjuvant chemotherapy in locally advanced tumors are currently unavailable. Our objective was to assess the effect of adjuvant chemotherapy and the impact of potential prognostic factors on survival in high‐risk, postsurgical UUT‐UC patients.


BJUI | 2014

Early unclamping technique during robot-assisted laparoscopic partial nephrectomy can minimise warm ischaemia without increasing morbidity.

Benoit Peyronnet; H. Baumert; Romain Mathieu; Alexandra Masson-Lecomte; Y. Grassano; Mathieu Roumiguié; W. Massoud; Vincent Abd El Fattah; Franck Bruyère; S. Droupy; Alexandre de la Taille; N. Doumerc; Jean-Christophe Bernhard; Christophe Vaessen; Morgan Rouprêt; K. Bensalah

To compare perioperative outcomes of early unclamping (EUC) vs standard unclamping (SUC) during robot‐assisted partial nephrectomy (RAPN), as early unclamping of the renal pedicle has been reported to decrease warm ischaemia time (WIT) during laparoscopic PN.


Neurourology and Urodynamics | 2011

Prospective study of the impact on quality of life of cystectomy with ileal conduit urinary diversion for neurogenic bladder dysfunction.

Julien Guillotreau; E. Castel-Lacanal; Mathieu Roumiguié; Benoit Bordier; Nicolas Doumerc; Xavier De Boissezon; Bernard Malavaud; P. Marque; Pascal Rischmann; Xavier Gamé

Neurogenic bladder dysfunction has a negative impact on the patients quality of life (QoL). Cystectomy with ileal conduit urinary diversion is a treatment option in patients in failure after conservative management. The objective of this study was to evaluate the impact of ileal conduit urinary diversion on the QoL of patients with neurogenic bladder dysfunction.


BJUI | 2012

The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study

Alexis Arvin Berod; Pierre Colin; David R. Yates; Adil Ouzzane; M. Audouin; Emilie Adam; Frédéric Arroua; Charles Marchand; Pierre Bigot; Michel Soulie; Mathieu Roumiguié; Thomas Polguer; Solène Gardic; Pascal Gres; Emmanuel Ravier; Y. Neuzillet; Francky Delage; Thomas Bodin; Géraldine Pignot; Morgan Rouprêt

Study Type – Prognosis (cohort)


Ejso | 2013

Robot-assisted laparoscopic nephron sparing surgery for tumors over 4 cm: Operative results and preliminary oncologic outcomes from a multicentre French study

A. Masson-Lecomte; D.R. Yates; Karim Bensalah; C. Vaessen; A. De La Taille; Mathieu Roumiguié; N. Doumerc; F. Bruyère; L. Soustelle; S. Droupy; Morgan Rouprêt

OBJECTIVE To assess operative and pathological results obtained after robot-assisted partial nephrectomy (RAPN) in renal masses over 4 cm. PATIENTS AND METHODS Between 2007 and 2011, 220 robotic nephron-sparing surgeries (NSS) were performed at six French urology departments. Data were prospectively collected: age, BMI, pre and post-operative eGFR (MDRD), operative time (OT), warm ischemia time (WIT), estimated blood loss (EBL), length of hospital stay (LOS), Clavien complications, pathological results and oncologic outcome. Tumor complexity was assessed according to the RENAL nephrometry score. RESULTS Overall, 54 tumors were included. Median follow up was 26 months. Median age at surgery was 62 years. Median RENAL nephrometry score was 7 (4-10). Median WIT was 23 min (10-59). Median OT and EBL were 180 min (110-425) and 100 cc (0-2500). Blood transfusion occurred in 7 cases (13%). Median tumor size was 45 mm (40-70). Three patients had positive surgical margins. Median LOS was 5 days (2-28). Nine patients presented post-operative complications of which 1/3 were considered as major (Clavien IIIb). Median pre-operative and post-operative eGFR was 88 (36-136) and 75 ml/min (33-122) (p = 0.01), respectively. Two patients developed subsequent metastasis. The 2-year progression free survival (PFS) rate was 90.5%. CONCLUSION Our results confirm that RAPN is a useful and acceptable approach for renal masses greater than 4 cm in size. When technically possible, NSS provides promising short-term cancer-specific survival rates with acceptable morbidity. Tumor size is not sufficiently discriminant enough and RENAL nephrometry score should increasingly used to describe tumor complexity.


Neurourology and Urodynamics | 2016

Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity

Benoit Peyronnet; Mathieu Roumiguié; E. Castel-Lacanal; Julien Guillotreau; Bernard Malavaud; P. Marque; Pascal Rischmann; Xavier Gamé

To assess the results of onabotulinum toxin detrusor injections when abobotulinum toxin detrusor injection failed.


The Journal of Urology | 2016

Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?

Nicolas Barry Delongchamps; D. Portalez; Eric Bruguière; Bernard Malavaud; Pierre Mozer; G. Fiard; F. Cornud; Caroline Escourrou; Stéphanie Renault; Naïm Bouazza; Jean-Michel Casanova; Arachk de Gorski; R. Renard-Penna; Mathieu Roumiguié; M. Thoulouzan; V. Misrai; Julien Guillotreau; Richard Aziza; Jean-Luc Descotes; N. Hohn; Flavie Bratan; Fanny Cros; Thomas Sanzalone

PURPOSE In men with suspicion of prostate cancer the standard of cancer detection is transrectal ultrasound guided 10 to 12-core systematic biopsy. The targeted biopsy only strategy using magnetic resonance imaging-transrectal ultrasound image registration is gaining in popularity. We assessed the noninferiority of targeted vs systematic biopsy. MATERIALS AND METHODS Between June and October 2014 a total of 108 biopsy naïve patients with prostate specific antigen between 4 and 20 ng/ml, normal rectal examination and a single suspicious image on magnetic resonance imaging were included in study at 7 centers. Patients underwent systematic biopsy by a first operator blinded to magnetic resonance imaging, immediately followed by 3 targeted biopsies within the suspicious image by a second operator. The primary end point was the cancer detection rate. The noninferiority margin was set at -5%. The secondary end points were the detection rate of clinically significant prostate cancer (maximum cancer core length 5 mm or greater for Gleason 6 or any Gleason 7 or greater disease) and procedure duration. RESULTS Systematic and targeted biopsies detected cancer in 66 (61.1%) and 61 patients (56.5%), respectively. The mean difference was -4.5% with a 95% CI lower bound of -11.8%. A total of 13 patients with protocol violations were excluded from the per protocol analysis, which showed a mean difference of -5.2% with a 95% CI lower bound of -13.1%. Clinically significant prostate cancer was detected in 50 (46.2%) and 52 patients (48.1%) with systematic and targeted biopsies, respectively (p = 0.69). The mean ± SD duration of image fusion plus targeted biopsy was 16.7 ± 7 minutes vs 7.4 ± 3 for systematic biopsy (p <0.001). CONCLUSIONS Targeted biopsy seemed to be inferior to systematic biopsy for overall cancer detection. Detection of clinically significant prostate cancer did not differ between targeted and systematic biopsies.


European Urology | 2015

Totally Robotic Approach with Transvaginal Insertion for Kidney Transplantation

Nicolas Doumerc; Mathieu Roumiguié; Pascal Rischmann; F. Sallusto

We report the first totally robotic procedure for kidney transplantation with transvaginal insertion. The initial results suggested reduced pain and improved cosmesis and the absence of lymphocele formation without compromising graft function or patient outcome. The patient was a 50-yr-old woman who received a living donor transplant for end-stage chronic kidney disease. We used a 4-arm Si HD da Vinci robot (Intuitive Surgical Inc., Sunnyvale, CA, USA) with standard port placement. The following procedural steps were performed sequentially: transperitoneal dissection of the external vessels, uterine mobilisation with transparietal stitching to allow full visualisation of the posterior vaginal wall to be used for graft insertion (through an Alexis retractor [Applied Medical,


BJUI | 2014

External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.

Mathieu Roumiguié; Jean-Baptiste Beauval; Thomas Filleron; Thibaut Benoit; Pascal Rischmann; Alexandre de la Taille; Laurent Salomon; Michel Soulie; Bernard Malavaud; Guillaume Ploussard

To establish an external validation of the updated nomogram from Briganti et al., which provides estimates of the probability of specimen‐confined disease using the variables age, prostate‐specific antigen (PSA), clinical stage and biopsy Gleason score in preoperatively defined high‐risk prostate cancer (PCa).

Collaboration


Dive into the Mathieu Roumiguié's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Xavier Gamé

UCL Institute of Neurology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge